New Approaches to Clinical Trials for Rare Diseases: Decentralized Trial Design for Neurofibromatosis Type 1 and Schwannomatosis
Authors:
- Vanessa L. MerkerVMVanessa L. Merker
- Shivani AhlawatSAShivani Ahlawat
- Robert A. AveryRARobert A. Avery
- Diana BradfordDBDiana Bradford
- Andrea M. GrossAGAndrea M. Gross
- Jennifer JanuszJJJennifer Janusz
- Andrés J. LessingALAndrés J. Lessing
- Linda ManthLMLinda Manth
- Miranda L. McManusMMMiranda L. McManus
- Beverly OberlanderBOBeverly Oberlander
- Dominique C. PichardDPDominique C. Pichard
- William RiterWRWilliam Riter
Open Access
Abstract
Background: In decentralized clinical trials, some or all activities occur outside of traditional sites, which may reduce time away from school/work and decrease participation burden for patients and their parents/caregivers. This methodology may improve recruitment and retention in studies, which is important for rare diseases like neurofibromatosis type 1 (NF1) and schwannomatosis (SWN). Published guidance exists for the general conduct of decentralized trials, but specific considerations for clinical trial design and endpoints in NF1/SWN have not yet been explored. Methods: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration is a group of researchers, clinicians, and people affected by NF1 and SWN whose shared goal is to advance clinical trial methodology for NF1/SWN. In December 2023, REiNS members met to discuss the opportunities and challenges of conducting NF1/SWN decentralized trials. Results: Endpoints that are promising for use in NF1/SWN decentralized trials include visual acuity (as tested by the computerized amblyopia treatment study HOTV testing algorithm); electronic versions of REiNS-recommended patient reported outcome measures; digital health technologies for functional outcomes; radiography and computed tomography scans for imaging outcomes; remote photography to assess cutaneous neurofibromas; “e-centralized” evaluations of neurocognitive functioning; and remote biomarkers collected with analyte stabilizing tubes and self-collection devices. Conclusions: Further research is necessary to validate endpoints for decentralized trials for NF1/SWN and evaluate their feasibility. However, trial designs that incorporate decentralized elements hold considerable promise for rare diseases like NF1/SWN where patients encounter significant barriers to traditional clinical trial participation.Keywords
Funding Information
- Children's Tumor Foundation
- Texas Neurofibromatosis Foundation
- NF Midwest
- NF Michigan
- NF North Central
- NF Northeast
- National Institute of Health (CA236536)
- National Institute of Health (CA180886-S1)
- National Institute of Health (EY029687)
- Gilbert Family Foundation
This publication has 74 references indexed in Scilit:
- Academic Achievement of Children and Adolescents with Neurofibromatosis Type 1: A Systematic Review and Meta-AnalysisNeuropsychology Review, 2025
- The clinical spectrum of paediatric NF2- related schwannomatosisFamilial Cancer, 2025
- Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With NeurofibromatosisJAMA Network Open, 2023
- Imaging of pediatric brain tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White PaperPediatric Blood & Cancer, 2022
- Development of an application for mobile phones (App) capable to predict the improvement of the degree House Brackmann scale in patients suffering from iatrogenic facial palsyAdvances in Oral and Maxillofacial Surgery, 2022
- Regulatory Acceptance of Patient-Reported Outcome (PRO) Data from Bring-Your-Own-Device (BYOD) Solutions to Support Medical Product Labeling ClaimsTherapeutic Innovation & Regulatory Science, 2022
- Management of spinal deformities and tibial pseudarthrosis in children with neurofibromatosis type 1 (NF-1)Child's Nervous System, 2020
- Capturing Patient-Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO Measurement in Clinical TrialsThe Patient - Patient-Centered Outcomes Research, 2014
- Retinal Nerve Fiber Layer Thickness in Children With Optic Pathway GliomasAmerican Journal of Ophthalmology, 2011
- Clinic-based study of plexiform neurofibromas in neurofibromatosis 1American Journal of Medical Genetics, 2000